| Drug General Information |
| Drug ID |
D0F6WV
|
| Former ID |
DCL000917
|
| Drug Name |
PD-157695
|
| Drug Type |
Small molecular drug
|
| Indication |
Schizophrenia [ICD9: 295; ICD10:F20]
|
Preclinical |
[1]
|
|---|
| Company |
Pfizer
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C13H10BrN3O4
|
| Canonical SMILES |
C1=CC=C(C(=C1)NC(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])O)Br
|
| InChI |
1S/C13H10BrN3O4/c14-9-3-1-2-4-10(9)15-13(19)16-11-6-5-8(17(20)21)7-12(11)18/h1-7,18H,(H2,15,16,19)
|
| InChIKey |
MQBZVUNNWUIPMK-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
5591039, 7980570, 9993997, 14852033, 26759489, 41934772, 48110581, 49684195, 50112982, 50221429, 53788115, 53800548, 57356606, 85209285, 85787141, 97803300, 99431513, 103547644, 104082381, 106118934, 112404235, 121380087, 125333764, 125433058, 128631686, 134339365, 134340331, 134340490, 134340502, 134964511, 135293912, 135650994, 135698246, 139121540, 162023547, 163124986, 163687365, 167450927, 187071964, 196399953, 204360502, 208264769, 223427138, 223777318, 227354209, 252156740, 252457432, 252473340
|
| Target and Pathway |
| Target(s) |
D(2) dopamine receptor |
Target Info |
Antagonist |
[1]
|
|---|
| D(3) dopamine receptor |
Target Info |
Antagonist |
[1]
|
|
KEGG Pathway
|
Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholismhsa04080:Neuroactive ligand-receptor interaction
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
Reactome
|
Dopamine receptors
|
|
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
Nicotine Activity on Dopaminergic NeuronsWP58:Monoamine GPCRs
|
|
Nicotine Activity on Dopaminergic Neurons
|
|
GPCRs, Other
|
| References |
| REF 1 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31. |
|---|
